zoledronic acid
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Prostate Cancer With Bone Metastasis
Conditions
Prostate Cancer With Bone Metastasis
Trial Timeline
Sep 1, 2003 → —
NCT ID
NCT00241111About zoledronic acid
zoledronic acid is a approved stage product being developed by Novartis for Prostate Cancer With Bone Metastasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00241111. Target conditions include Prostate Cancer With Bone Metastasis.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer With Bone Metastasis were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01197300 | Phase 3 | Completed |
| NCT01087008 | Approved | Completed |
| NCT01004510 | Phase 2 | Terminated |
| NCT00909961 | Phase 3 | Completed |
| NCT00966992 | Phase 2 | Terminated |
| NCT00760370 | Phase 2 | Completed |
| NCT00774020 | Approved | Completed |
| NCT00740129 | Approved | Completed |
| NCT00745485 | Approved | Completed |
| NCT00477217 | Phase 2 | Withdrawn |
| NCT00622505 | Approved | Completed |
| NCT00982124 | Phase 3 | Completed |
| NCT01218035 | Approved | Completed |
| NCT00434447 | Approved | Completed |
| NCT00424983 | Phase 1 | Completed |
| NCT00391950 | Phase 3 | Terminated |
| NCT00361595 | Pre-clinical | Completed |
| NCT00334139 | Approved | Completed |
| NCT00391690 | Approved | Completed |
| NCT00375427 | Phase 3 | Completed |
Competing Products
20 competing products in Prostate Cancer With Bone Metastasis